Clinical Trial: Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846541) titled 'Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis' on Jan. 27.

Brief Summary: The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are:

* How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis?

* Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis?

Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. Aft...